PaxMedica (MEX:PXMD) Notes Receivable: MXN0.00 Mil (As of Sep. 2024)


MEX:PXMD PaxMedica Inc MEX:PXMD
20 GF Score
Price MXN15.69
View Full Analysis

What is PaxMedica Notes Receivable?

PaxMedica MEX:PXMD 20 Notes Receivable is MXN0.00 Mil as of Sep. 2024. GuruFocus rates MEX:PXMD with a GF Score™ of 20/100.

PaxMedica's Notes Receivable for the quarter that ended in Sep. 2024 was MXN0.00 Mil.

PaxMedica Notes Receivable Historical Data

* Premium members only.

The historical data trend for PaxMedica's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PaxMedica Notes Receivable Chart

PaxMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

PaxMedica Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:PXMD
20GF Score
PaxMedica Inc MEX:PXMD
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PaxMedica Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of MXN0.00 Mil mean?
PaxMedica (MEX:PXMD) has a Notes Receivable of MXN0.00 Mil as of Sep. 2024. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on PaxMedica and its competitors.
Is PaxMedica's Notes Receivable too high?
PaxMedica's current Notes Receivable is MXN0.00 Mil. Overall, PaxMedica has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does PaxMedica's Notes Receivable compare to BTAX and NBIO?
PaxMedica's Notes Receivable of MXN0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on PaxMedica and its competitors. PaxMedica's current Notes Receivable is MXN0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PaxMedica stock overvalued right now?
PaxMedica (MEX:PXMD) has a current Notes Receivable of MXN0.00 Mil. The current Notes Receivable is MXN0.00 Mil. PaxMedica's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For PaxMedica (MEX:PXMD), the current Notes Receivable is MXN0.00 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PaxMedica Business Description

Address 303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
20GF Score

Get the complete analysis for MEX:PXMD

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN15.69
Price